Dr. Sanjay Waghani
MBBS, MD, DM (Cardiology)
Interventional Cardiologist

A study involving 50 patients with heart failure and impaired systemic right ventricle systolic function found that sacubitril / valsartan reduces hospitalization rates and mortality. The study included patients with transposition of the great arteries following Senning/Mustard procedure or congenitally corrected transposition of the great arteries. The primary end points included sacubitril/valsartan safety and efficacy, NT-proBNP, systolic function improvement, New York Heart Association class, 6-minute walking distance, and quality of life change. The study found that sacubitril/valsartan is well tolerated, associated with systemic right ventricle remodeling, improved systolic function, and improved clinical status, supporting its use in this complex population.

Click Here to view the article:

Aha Journals